

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1204rxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:10:45 ON 22 DEC 2006

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:11:11 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0
DICTIONARY FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen



ENTER SCREEN EXPRESSION OR (END):end

=> screen 1992 OR 2008 OR 2016 OR 2021 OR 2026 OR 1938 OR 1840

L1 SCREEN CREATED

=>

Uploading C:\Documents and Settings\rkeys\My Documents\STNEXP4\TEMPLATE\STANDARD\10700383.str



```

chain nodes :
7 8 16 17 19 20 25 26
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
5-7 7-8 8-9 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
16-17
exact bonds :
5-7 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

```

G1:Cl,F,CF3,OH, [*1]

G2:Cl,F,CF3,OH,H, [*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 19:CLASS 20:CLASS 22:Atom
23:Atom 25:CLASS 26:CLASS 27:Atom 28:Atom

L2 STRUCTURE UPLOADED

=> que L2 NOT L1

L3 QUE L2 NOT L1

=> s 13

SAMPLE SEARCH INITIATED 17:12:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 371 TO ITERATE

100.0% PROCESSED 371 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6265 TO 8575
PROJECTED ANSWERS: 931 TO 1949

L4 50 SEA SSS SAM L2 NOT L1

=> d scan

L4 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1,3-Benzenediol, 5-[(1E)-2-(2,4-dihydroxyphenyl)ethenyl]-2-[(1E)-3-methyl-
1-butenyl]- (9CI)
MF C19 H20 O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 13 ful
FULL SEARCH INITIATED 17:13:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7357 TO ITERATE

100.0% PROCESSED 7357 ITERATIONS 1209 ANSWERS
SEARCH TIME: 00.00.01

L5 1209 SEA SSS FUL L2 NOT L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
168.26	168.47

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:13:27 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5 and pharmaceutical composition

4312 L5
228626 PHARMACEUTICAL
672002 COMPOSITION
3967 PHARMACEUTICAL COMPOSITION
(PHARMACEUTICAL(W)COMPOSITION)
L6 9 L5 AND PHARMACEUTICAL COMPOSITION

=> d scan 1-9

'1-9' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

L6 9 ANSWERS CAPLUS COPYRIGHT 2006 ACS on STN
IC ICM A61K035-72
ICS A61K035-72; A61K031-05
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
TI Pharmaceutical composition containing polyphenols from
grapes, in particular resveratrol, and yeast extracts
ST oral pharmaceutical polyphenol grape resveratrol yeast
IT Drug delivery systems
(capsules; pharmaceutical composition containing polyphenols from grapes and
yeast exts.)
IT Cardiovascular system
Digestive tract
(disease; pharmaceutical composition containing polyphenols from grapes and
yeast exts.)
IT Yeast
(extract; pharmaceutical composition containing polyphenols from grapes and
yeast
exts.)
IT Drug delivery systems
(granules; pharmaceutical composition containing polyphenols from grapes and
yeast exts.)
IT Drug delivery systems
(oral; pharmaceutical composition containing polyphenols from grapes and
yeast
exts.)
IT Aging, animal
Hypoxia, animal
Saccharomyces cerevisiae
(pharmaceutical composition containing polyphenols from grapes and yeast
exts.)
IT Anthocyanins
Phenols, biological studies
Phytoalexins
Proanthocyanidins
Salts, biological studies

Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT Radicals, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT Phenols, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyphenols, nonpolymeric; pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT Drug delivery systems

(syrups; pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT Drug delivery systems

(tablets; pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT Biological transport

(uptake; pharmaceutical composition containing polyphenols from grapes and yeast exts.)

IT 59-43-8, Vitamin b1, biological studies 79-83-4, Pantothenic acid

83-88-5, Vitamin b2, biological studies 490-46-0, Epicatechin

501-36-0, Resveratrol 501-36-0D, trans-Resveratrol,

glycosides 1406-18-4, Vitamin e 7235-40-7, β -Carotene

7439-95-4D, Magnesium, salts, biological studies 7440-50-8D, Copper,

salts, biological studies 7440-66-6D, Zinc, salts, biological studies

7782-49-2D, Selenium, salts, biological studies 8059-24-3, Vitamin b6

61434-67-1, cis-Resveratrol 61434-67-1D,

cis-Resveratrol, glycosides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition containing polyphenols from grapes and yeast exts.)

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

CLASS ----- IPC, NCL, ECLA, FTERM

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

IND ----- Indexing data

IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE

PATS ----- PI, SO

SAM ----- CC, SX, TI, ST, IT

SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;

SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 17:10:45 ON 22 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:11:11 ON 22 DEC 2006

L1 SCREEN 1992 OR 2008 OR 2016 OR 2021 OR 2026 OR 1938 OR 18
 L2 STRUCTURE UPLOADED
 L3 QUE L2 NOT L1
 L4 50 S L3
 L5 1209 S L3 FUL

FILE 'CAPLUS' ENTERED AT 17:13:27 ON 22 DEC 2006

L6 9 S L5 AND PHARMACEUTICAL COMPOSITION

=> d 1-9 bib fhitr

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:845682 CAPLUS
 DN 145:256186
 TI Pharmaceutical composition comprising curcumin and

resveratrol
 IN Turini, Damiano; Coccoloni, Stefan
 PA Safi Investment Holding AG, Italy
 SO PCT Int. Appl., 16pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006087759	A2	20060824	WO 2006-IT93	20060221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI IT 2005-FI31 A 20050221


IT 501-36-0, Resveratrol

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical comps. comprising curcumin and resveratrol)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1255431 CAPLUS

DN 144:94217

TI A pharmaceutical composition containing panax
 notoginsenosides and glycosides of rheum nobile, and its preparation
 method

IN Hu, Qun

PA Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1611224	A	20050504	CN 2003-10110848	20031101

PRAI CN 2003-10110848

20031101

IT 10083-24-6

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(pharmaceutical composition containing panax notoginsenosides and glycosides of

rheum nobile, and its preparation method)

RN 10083-24-6 CAPLUS

CN 1,2-Benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1059181 CAPLUS

DN 142:33000

TI Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin

IN Deby, Carol; Dupont, Ginette; Serteyn, Didier

PA Universite de Liege, Belg.

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004105769	A1	20041209	WO 2004-BE78	20040528
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1644006	A1	20060412	EP 2004-735165	20040528
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	US 2006252707	A1	20061109	US 2005-558503	20051128
PRAI	EP 2003-447132	A	20030528		
	WO 2004-BE78	W	20040528		
OS	MARPAT 142:33000				
IT	501-36-0, trans-Resveratrol				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical composition for treatment and/or prevention of
atherosclerosis from infectious origin)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:867422 CAPLUS

DN 142:120445

TI Pharmaceutical composition for treatment of
periodontal diseases and anti-inflammation

IN Kim, Mun Mu; Seok, Jae Gyun; Kim, Sang Nyeon; Kim, Jeong Hun; Park, Sang
Gi; Lee, Hak Mo

PA LG Chemical Co., Ltd., S. Korea

SO Repub. Korean Kongkae Taeho Kongbo, No pp. given

CODEN: KRXXA7

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 2000041190	A	20000715	KR 1998-56996	19981222
PRAI	KR 1998-56996		19981222		

IT 501-36-0, Resveratrol


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(composition for treatment of periodontal diseases and inflammation)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
NAME)


Double bond geometry as shown.



L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:823314 CAPLUS
 DN 139:312478
 TI Pharmaceutical composition for prevention of blood
 circulation disorder containing PPAR α -activating agents
 IN Namura, Naotake; Inoue, Hiroyasu
 PA National Cardiovascular Center, Japan
 SO Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003300904	A	20031021	JP 2002-104049	20020405
PRAI	JP 2002-104049		20020405		
IT	501-36-0, Resveratrol				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pharmaceutical composition for prevention of blood circulation disorder containing PPAR α -activating agents)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:276670 CAPLUS
 DN 138:292768
 TI Cytotoxic pharmaceutical composition containing
 natural products
 IN Farley, Michael Donald
 PA USA
 SO U.S., 3 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6544564	B1	20030408	US 2001-995173	20011127
PRAI	US 2001-995173		20011127		
IT	501-36-0, Resveratrol				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(cytotoxic pharmaceutical composition containing natural products)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

1 400,000

NAME)

Double bond geometry as shown.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:173429 CAPLUS
DN 138:198599
TI Stilbene derivative with cytochrome P450 1B1 inhibitory activity,
pharmaceutically acceptable salt, preparation method,
pharmaceutical composition, and use in prevention of
carcinogenesis
IN Kim, Sang-Hee; Chun, Young-Jin
PA Promeditech, Inc., S. Korea
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018013	A1	20030306	WO 2002-KR977	20020523
	WO 2003018013	B1	20040408		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	KR 2003018800	A	20030306	KR 2001-53363	20010831
PRAI	KR 2001-53363	A	20010831		
OS	MARPAT 138:198599				
IT	22255-22-7P				
	RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(stilbene derivs. for cytochrome P 450 1B1 inhibitors, preparation, pharmaceutical composition, and use in prevention of carcinogenesis)				
RN	22255-22-7 CAPLUS				
CN	Benzene, 1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:43107 CAPLUS

DN 138:61295

TI A pharmaceutical composition containing natural
extracts and antioxidants and its use in arthropathy treatment

IN Stankov, Bojidar M.

PA Ambros Pharma S.r.l., Italy

SO Ital. Appl., 24 pp.

CODEN: ITXXCZ

DT Patent

LA Italian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IT 2000MI1092	A1	20011119	IT 2000-MI1092	20000517
	IT 1318523	B1	20030827		
PRAI	IT 2000-MI1092		20000517		

IT 501-36-0, Resveratrol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition containing natural exts. and antioxidants and


its

use in arthropathy treatment)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:48637 CAPLUS

DN 130:100692

TI Pharmaceutical composition containing polyphenols from
grapes, in particular resveratrol, and yeast extracts


IN Osterwalder, Nicolo

10/94

PA Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A., Italy
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901148	A1	19990114	WO 1998-EP4065	19980701
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CH 692837	A5	20021129	CH 1997-1598	19970702
	EP 925068	A1	19990630	EP 1998-936405	19980701
	EP 925068	B1	20030917		
	R: IT				
PRAI	CH 1997-1598	A	19970702		
	WO 1998-EP4065	W	19980701		
IT	501-36-0, Resveratrol				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pharmaceutical composition containing polyphenols from grapes and yeast exts.)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
36.87	205.34

FILE 'STNGUIDE' ENTERED AT 17:15:00 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> SET NOTICE DISPLAY 1

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> set auhelp off; set smart off; set msteps off; set expand cont; set audit off;
del sel y

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> FILE CAPLUS,WPINDEX

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	205.76

FILE 'CAPLUS' ENTERED AT 17:19:22 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS).

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S KR 2000041190/PN,APPS

1 KR 2000041190/PN
(KR2000041190/PN)
0 KR 2000041190/AP
0 KR 2000041190/PRN

07.12.07

0 KR 2000041190/APPS
(KR 2000041190/AP, PRN)
L7 1 KR 2000041190/PN, APPS

=> FILE INPADOC

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.31	212.07

FILE 'INPADOC' ENTERED AT 17:19:24 ON 22 DEC 2006
COPYRIGHT (C) 2006 European Patent Office, Vienna (EPO)

FILE LAST UPDATED: 21 DEC 2006 <20061221/UP>
21 DEC 2006 <20061221/UPLS>
MOST RECENT INPADOC WEEK: 200651 <200651/EW>
FILE COVERS 1968 TO DATE.

>>> FOR STATISTIC OF CURRENT WEEK'S NEW ENTRIES,
ENTER HELP UPS <<<

>>> STATISTIC FOR UPDATES OF PUBLICATION/PATENT KIND CODES
A. SORTED BY COUNTRY:
<http://www.stn-international.de/stndatabases/details/inpadoc/fkd1>
B. SORTED BY DATE:
<http://www.stn-international.de/stndatabases/details/inpadoc/fkd2> <<<

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html <<<

>>> NEW IPC8 SEARCH, DISPLAY, AND SELECT ENHANCEMENTS ! --> SEE NEWS <<<
>>> A thesaurus is available in the /IPC search field --> SEE NEWS <<<
>>> FOR CHANGES IN INPADOC SEE HELP CHANGE (last updated February 16, 2006) <<<

>>> KOREAN PATENT DOCUMENTS are now part of the PCT minimum documentation.
- The EPO has re-keyed KR priorities due to PRN number format corrections.
- In addition the INPADOC updates contain now and for the next weeks a
high number of KR documents to fill the gaps. <<<

>>> A big reload of French abstracts will be delivered in week 46-51/2006
in portions of about 100,000 documents per update. <<<

=> TRA L7 PN

L8 TRANSFER L7 1- PN : 1 TERM
L9 0 L8

=>

=>

No English language equivalents could be found for this Patent Number

=> set auhelp login; set smart login; set msteps login; set expand login; set
audit login

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> d his

(FILE 'HOME' ENTERED AT 17:10:45 ON 22 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:11:11 ON 22 DEC 2006

L1 SCREEN 1992 OR 2008 OR 2016 OR 2021 OR 2026 OR 1938 OR 18
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 50 S L3
L5 1209 S L3 FUL

FILE 'CAPLUS' ENTERED AT 17:13:27 ON 22 DEC 2006

L6 9 S L5 AND PHARMACEUTICAL COMPOSITION

FILE 'STNGUIDE' ENTERED AT 17:15:00 ON 22 DEC 2006

SET NOTICE DISPLAY 1
SET AUHELP OFF
SET SMART OFF
SET MSTEPS OFF
SET EXPAND CONT
SET AUDIT OFF
DEL SEL Y

FILE 'CAPLUS' ENTERED AT 17:19:22 ON 22 DEC 2006

L7 1 S KR 2000041190/PN,APPS

FILE 'INPADOC' ENTERED AT 17:19:24 ON 22 DEC 2006

FILE 'CAPLUS' ENTERED AT 17:19:26 ON 22 DEC 2006

L8 TRA L7 1- PN : 1 TERM

FILE 'INPADOC' ENTERED AT 17:19:27 ON 22 DEC 2006

L9 0 SEA L8
SET AUHELP LOGIN
SET SMART LOGIN
SET MSTEPS LOGIN
SET EXPAND LOGIN
SET AUDIT LOGIN
SET NOTICE LOGIN DISPLAY

=> SET NOTICE DISPLAY 1

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> set auhelp off; set smart off; set msteps off; set expand cont; set audit off;
del sel y

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> FILE CAPLUS,WPINDEX

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.91	225.20

FILE 'CAPLUS' ENTERED AT 17:20:08 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S IT 1318523/PN,APPS

```
      1 IT 1318523/PN
        (IT1318523/PN)
      0 IT 1318523/AP
      0 IT 1318523/PRN
      0 IT 1318523/APPS
        (IT 1318523/AP,PRN)
L10    1 IT 1318523/PN,APPS
```

=> FILE INPADO

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.31	231.51

FILE 'INPADO' ENTERED AT 17:20:10 ON 22 DEC 2006

COPYRIGHT (C) 2006 European Patent Office, Vienna (EPO)

FILE LAST UPDATED: 21 DEC 2006 <20061221/UP>
21 DEC 2006 <20061221/UPLS>
MOST RECENT INPADOC WEEK: 200651 <200651/EW>
FILE COVERS 1968 TO DATE.

>>> FOR STATISTIC OF CURRENT WEEK'S NEW ENTRIES,
ENTER HELP UPS <<<

>>> STATISTIC FOR UPDATES OF PUBLICATION/PATENT KIND CODES

A. SORTED BY COUNTRY:

<http://www.stn-international.de/stndatabases/details/inpadoc/fkd1>

B. SORTED BY DATE:

<http://www.stn-international.de/stndatabases/details/inpadoc/fkd2> <<<

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html <<<

>>> NEW IPC8 SEARCH, DISPLAY, AND SELECT ENHANCEMENTS ! --> SEE NEWS <<<

>>> A thesaurus is available in the /IPC search field --> SEE NEWS <<<

>>> FOR CHANGES IN INPADOC SEE HELP CHANGE (last updated February 16, 2006) <<<

>>> KOREAN PATENT DOCUMENTS are now part of the PCT minimum documentation.

- The EPO has re-keyed KR priorities due to PRN number format corrections.

- In addition the INPADOC updates contain now and for the next weeks a
high number of KR documents to fill the gaps. <<<

>>> A big reload of French abstracts will be delivered in week 46-51/2006
in portions of about 100,000 documents per update. <<<

=> TRA L10 PN

L11 TRANSFER L10 1- PN : 2 TERMS
L12 1 L11

=>

=> S L12 AND US/PC

4746338 US/PC
L13 0 L12 AND US/PC

=> SEL PN

L13 HAS NO ANSWERS

=> S L12 AND ZA/PC

207619 ZA/PC
L14 0 L12 AND ZA/PC

=> SEL PN

L14 HAS NO ANSWERS

=> S L12 AND EP/PC AND EN/LA

1733956 EP/PC
3569298 EN/LA
L15 0 L12 AND EP/PC AND EN/LA

=> SEL PN

L15 HAS NO ANSWERS

=> S L12 AND WO/PC AND EN/LA

1202174 WO/PC

3569298 EN/LA

L16 0 L12 AND WO/PC AND EN/LA

=> SEL PN

L16 HAS NO ANSWERS

=> S L12 AND AU/PC

967453 AU/PC

L17 0 L12 AND AU/PC

=> SEL PN

L17 HAS NO ANSWERS

=> S L12 AND CA/PC AND EN/LA

968602 CA/PC

3569298 EN/LA

L18 0 L12 AND CA/PC AND EN/LA

=> SEL PN

L18 HAS NO ANSWERS

=> D SELECT

NO E# DEFINED

No English language equivalents could be found for this Patent Number

=> set auhelp login; set smart login; set msteps login; set expand login; set
audit login

=> SET NOTICE LOGIN DISPLAY

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=>

NOTICE SET TO OFF FOR DISPLAY COMMAND

SET COMMAND COMPLETED

12,410

=> d his

(FILE 'HOME' ENTERED AT 17:10:45 ON 22 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:11:11 ON 22 DEC 2006

L1 SCREEN 1992 OR 2008 OR 2016 OR 2021 OR 2026 OR 1938 OR 18
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 50 S L3
L5 1209 S L3 FUL

FILE 'CAPLUS' ENTERED AT 17:13:27 ON 22 DEC 2006

L6 9 S L5 AND PHARMACEUTICAL COMPOSITION

FILE 'STNGUIDE' ENTERED AT 17:15:00 ON 22 DEC 2006

SET NOTICE DISPLAY 1
SET AUHELP OFF
SET SMART OFF
SET MSTEPS OFF
SET EXPAND CONT
SET AUDIT OFF
DEL SEL Y

FILE 'CAPLUS' ENTERED AT 17:19:22 ON 22 DEC 2006

L7 1 S KR 2000041190/PN,APPS

FILE 'INPADOC' ENTERED AT 17:19:24 ON 22 DEC 2006

FILE 'CAPLUS' ENTERED AT 17:19:26 ON 22 DEC 2006

L8 TRA L7 1- PN : 1 TERM

FILE 'INPADOC' ENTERED AT 17:19:27 ON 22 DEC 2006

L9 0 SEA L8
SET AUHELP LOGIN
SET SMART LOGIN
SET MSTEPS LOGIN
SET EXPAND LOGIN
SET AUDIT LOGIN
SET NOTICE LOGIN DISPLAY
SET NOTICE DISPLAY 1
SET AUHELP OFF
SET SMART OFF
SET MSTEPS OFF
SET EXPAND CONT
SET AUDIT OFF
DEL SEL Y

FILE 'CAPLUS' ENTERED AT 17:20:08 ON 22 DEC 2006

L10 1 S IT 1318523/PN,APPS

FILE 'INPADOC' ENTERED AT 17:20:10 ON 22 DEC 2006

FILE 'CAPLUS' ENTERED AT 17:20:12 ON 22 DEC 2006

L11 TRA L10 1- PN : 2 TERMS

FILE 'INPADOC' ENTERED AT 17:20:13 ON 22 DEC 2006

L12 1 SEA L11
L13 0 S L12 AND US/PC
L14 0 S L12 AND ZA/PC
L15 0 S L12 AND EP/PC AND EN/LA
L16 0 S L12 AND WO/PC AND EN/LA
L17 0 S L12 AND AU/PC

L18 0 S L12 AND CA/PC AND EN/LA
 SET AUHELP LOGIN
 SET SMART LOGIN
 SET MSTEPS LOGIN
 SET EXPAND LOGIN
 SET AUDIT LOGIN
 SET NOTICE LOGIN DISPLAY

=> s l5 and (oral? or nasal? or parenteral? or topical?)
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
FULL ESTIMATED COST 4.55 248.28

FILE 'CAPLUS' ENTERED AT 17:22:54 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 17:10:45 ON 22 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:11:11 ON 22 DEC 2006

L1 SCREEN 1992 OR 2008 OR 2016 OR 2021 OR 2026 OR 1938 OR 18
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 50 S L3
L5 1209 S L3 FUL

L6 FILE 'CAPLUS' ENTERED AT 17:13:27 ON 22 DEC 2006
 9 S L5 AND PHARMACEUTICAL COMPOSITION

FILE 'STNGUIDE' ENTERED AT 17:15:00 ON 22 DEC 2006
 SET NOTICE DISPLAY 1
 SET AUHELP OFF

SET SMART OFF
SET MSTEPS OFF
SET EXPAND CONT
SET AUDIT OFF
DEL SEL Y

L7 FILE 'CAPLUS' ENTERED AT 17:19:22 ON 22 DEC 2006
1 S KR 2000041190/PN,APPS

FILE 'INPADOC' ENTERED AT 17:19:24 ON 22 DEC 2006

L8 FILE 'CAPLUS' ENTERED AT 17:19:26 ON 22 DEC 2006
TRA L7 1- PN : 1 TERM

L9 FILE 'INPADOC' ENTERED AT 17:19:27 ON 22 DEC 2006
0 SEA L8
SET AUHELP LOGIN
SET SMART LOGIN
SET MSTEPS LOGIN
SET EXPAND LOGIN
SET AUDIT LOGIN
SET NOTICE LOGIN DISPLAY
SET NOTICE DISPLAY 1
SET AUHELP OFF
SET SMART OFF
SET MSTEPS OFF
SET EXPAND CONT
SET AUDIT OFF
DEL SEL Y

L10 FILE 'CAPLUS' ENTERED AT 17:20:08 ON 22 DEC 2006
1 S IT 1318523/PN,APPS

FILE 'INPADOC' ENTERED AT 17:20:10 ON 22 DEC 2006

L11 FILE 'CAPLUS' ENTERED AT 17:20:12 ON 22 DEC 2006
TRA L10 1- PN : 2 TERMS

L12 FILE 'INPADOC' ENTERED AT 17:20:13 ON 22 DEC 2006
1 SEA L11
L13 0 S L12 AND US/PC
L14 0 S L12 AND ZA/PC
L15 0 S L12 AND EP/PC AND EN/LA
L16 0 S L12 AND WO/PC AND EN/LA
L17 0 S L12 AND AU/PC
L18 0 S L12 AND CA/PC AND EN/LA
SET AUHELP LOGIN
SET SMART LOGIN
SET MSTEPS LOGIN
SET EXPAND LOGIN
SET AUDIT LOGIN
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 17:22:54 ON 22 DEC 2006

=> s 15 and (oral? or nasal? or parenteral? or topical?)

4312 L5
261680 ORAL?
20580 NASAL?
28238 PARENTERAL?
49422 TOPICAL?

L19 291 L5 AND (ORAL? OR NASAL? OR PARENTERAL? OR TOPICAL?)

=> s 119 and (capsule? or drop? or syrup or spray or cream or ointment or shampoo or lotion or gel or solution)

65724 CAPSULE?
385826 DROP?
15581 SYRUP
130107 SPRAY
31929 CREAM
10976 OINTMENT
6484 SHAMPOO
7373 LOTION
499668 GEL
264260 SOLUTION

L20 82 L19 AND (CAPSULE? OR DROP? OR SYRUP OR SPRAY OR CREAM OR OINTMENT OR SHAMPOO OR LOTION OR GEL OR SOLUTION)

=> s 120 and 1700-2002/py
22830216 1700-2002/PY


L21 22 L20 AND 1700-2002/PY

=> d 1-22 bib fhitr

L21 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:293237 CAPLUS
DN 140:309008
TI Nanometer-sized oil-in-glycerin emulsions for enhanced skin permeation
IN Friedman, Doron I.
PA Israel
SO U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 700,862.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004067244	A1	20040408	US 2003-394111	20030321
	WO 2000056346	A1	20000928	WO 2000-IL142	20000309 <--
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,				
	IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,				
	MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6544530	B1	20030408	US 2001-700862	20010122
PRAI	IL 1999-129102	A	19990322		
	WO 2000-IL142	W	20000309		
	IL 2000-138616	A	20000921		
	WO 2000-IL826	A2	20001208		
	US 2001-700862	A2	20010122		
IT	501-36-0, Resveratrol				
	RL: NUU (Other use, unclassified); USES (Uses)				
	(skin-permeation-enhancing nanometer-sized emulsions containing glycerin				
	and bioactive compds. and vegetable oils and emulsifying stabilizers)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX				
	NAME)				

Double bond geometry as shown.




L21 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:492786 CAPLUS
 DN 139:21380
 TI Extraction of resveratrol from grape and its use in port wine
 IN Pan, Junqi
 PA Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 5 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1351985	A	20020605	CN 2000-113971	20001113 <--
PRAI	CN 2000-113971		20001113		
IT	501-36-0P, Resveratrol				
	RL: FFD (Food or feed use); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(extraction of resveratrol from grape and its use in beverage)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




L21 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:765839 CAPLUS
 DN 137:268203
 TI Maillard reaction inhibitors containing catechin or resveratrols, and topical or oral compositions containing them
 IN Kawai, Yasuhiro
 PA Sunstar, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002293736	A	20021009	JP 2001-98146	20010330 <--
PRAI	JP 2001-98146		20010330		
IT	501-36-0, Resveratrol RL: COS (Cosmetic use); FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical or oral Maillard reaction inhibitors containing catechin or resveratrols)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




L21 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:502829 CAPLUS
 DN 137:68172
 TI Pharmaceutical formulations of resveratrol for treatment of skin disorders
 IN Pezzuto, John M.; Moon, Richard C.; Jang, Mei-Shiang; Ouali, Aomar; Lin, Shengzhao; Barillas, Karla Slowing
 PA Pharmascience, Can.
 SO U.S., 15 pp., Cont.-in-part of U.S. 6,008,260.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6414037	B1	20020702	US 1999-430337	19991029 <--
	US 6008260	A	19991228	US 1998-5114	19980109 <--
	CA 2389167	A1	20010503	CA 2000-2389167	20001023 <--
	WO 2001030336	A2	20010503	WO 2000-US41488	20001023 <--
	WO 2001030336	A3	20011227		
	WO 2001030336	A9	20021227		
	W: CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1239849	A2	20020918	EP 2000-991709	20001023 <--
	EP 1239849	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 323473	T	20060515	AT 2000-991709	20001023
	PT 1239849	T	20060731	PT 2000-991709	20001023
	US 2002173472	A1	20021121	US 2002-71124	20020207 <--
PRAI	US 1998-5114	A2	19980109		
	AU 1998-88420	A	19981009		
	US 1999-430337	A	19991029		
	WO 2000-US41488	W	20001023		

IT 501-36-0, Resveratrol
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical resveratrol formulations for treatment of skin
 disorders)
 RN 501-36-0 CAPLUS
 CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:465780 CAPLUS
 DN 137:52026
 TI Cosmetic composition comprising 7-hydroxy DHEA and/or 7-keto DHEA and at
 least an anti-glycation agent
 IN Courchay, Guy; Roguet, Roland
 PA L'oreal, Fr.
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2

DT Patent
 LA French


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047648	A1	20020620	WO 2001-FR3641	20011120 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2818139	A1	20020621	FR 2000-16444	20001215 <--
FR 2818139	B1	20030214		
AU 2002021996	A5	20020624	AU 2002-21996	20011120 <--
PRAI FR 2000-16444	A	20001215		
WO 2001-FR3641	W	20011120		

IT 501-36-0, Resveratrol
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cosmetic composition comprising hydroxy-dehydroepiandrosterone derivs. and
 anti-glycation agent)
 RN 501-36-0 CAPLUS
 CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
 NAME)

10/700,383

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:129106 CAPLUS <<LOGINID::20061222>>

DN 136:189101

TI 5,5-Diaryl-2,4-pentadienoate esters, and UV absorbers and topical preparations containing them

IN Kobayashi, Toru; Ogura, Saneharu; Sakurai, Kazutoshi; Shiroyama, Kenichiro; Hagiwara, Toshimitsu

PA Takasago Perfumery Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002053527	A	20020219	JP 2000-242886	20000810 <--
PRAI	JP 2000-242886		20000810		
OS	MARPAT 136:189101				
IT	399530-94-0				

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of diarylpentadienoate esters as UV absorbers for cosmetics)

RN 399530-94-0 CAPLUS

CN Benzeneacetaldehyde, α -[(3,4-dimethoxyphenyl)methylene]-4-methoxy-
(9CI) (CA INDEX NAME)



L21 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:87133 CAPLUS <<LOGINID::20061222>>

DN 136:139630

TI Antiaging and antiwrinkle cosmetics comprising glycosylated hydroxystilbenes

IN Pruche, Francis; Bernard, Dominique; Mehul, Bruno


PA L'oreal, Fr.

SO Eur. Pat. Appl., 9 pp.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1175888	A2	20020130	EP 2001-401865	20010711 <--
	EP 1175888	A3	20030604		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2812195	A1	20020201	FR 2000-10008	20000728 <--
	FR 2812195	B1	20030711		
	CA 2354107	A1	20020128	CA 2001-2354107	20010725 <--
	US 2002051799	A1	20020502	US 2001-915353	20010727 <--
	JP 2002080372	A	20020319	JP 2001-230676	20010730 <--
PRAI	FR 2000-10008	A	20000728		
OS	MARPAT 136:139630				
IT	501-36-0, Resveratrol				
	RL: COS (Cosmetic use); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)				
	(antiaging and antiwrinkle cosmetics comprising glycosylated hydroxystilbenes)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




L21 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:71838 CAPLUS
 DN 136:123407
 TI Cosmetic compositions containing dehydroepiandrosterone or precursor or derivative thereof and a glycation inhibiting agent
 IN Courchay, Guy; Roguet, Roland
 PA L'oreal, Fr.
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002005777	A1	20020124	WO 2001-FR1790	20010608 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2811568	A1	20020118	FR 2000-9232	20000713 <--

FR 2811568 B1 20030117
 EP 1303253 A1 20030423 EP 2001-945388 20010608
 EP 1303253 B1 20040915
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRAI FR 2000-9232 A 20000713
 WO 2001-FR1790 W 20010608
 IT 501-36-0, Resveratrol
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cosmetic comps. containing dehydroepiandrosterone or precursor or
 derivative thereof and glycation inhibiting agent)
 RN 501-36-0 CAPLUS
 CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:885779 CAPLUS
 DN 136:11084
 TI Method for extraction of antitumor drugs from spermatophyte plants
 IN Ravagnan, Giampietro; Falchetti, Roberto; Lanzilli, Giulia; Fuggetta,
 Maria Pia; Tricarico, Maria; Mattivi, Fulvio
 PA Istituto di Neurobiologia e Medicina Molecolare del CNR, Italy; Istituto
 Agrario Di S. Michele All'adige; Consiglio Nazionale Delle Ricerche
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001091763	A2	20011206	WO 2001-IB981	20010529 <--
	WO 2001091763	A3	20020815		
	WO 2001091763	A9	20030508		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,				
	KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,				
	IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				
	GW, ML, MR, NE, SN, TD, TG				
	EP 1292319	A2	20030319	EP 2001-934245	20010529
	EP 1292319	B1	20051116		

10/34

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
AT 309814 T 20051215 AT 2001-934245 20010529
ES 2253378 T3 20060601 ES 2001-1934245 20010529
US 2004052879 A1 20040318 US 2003-296419 20030905
PRAI IT 2000-RM293 A 20000530
WO 2001-IB981 W 20010529
IT 501-36-0, trans-Resveratrol
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PEP
(Physical, engineering or chemical process); PYP (Physical process); THU
(Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC
(Process); USES (Uses)
(method for extraction of antitumor drugs from spermatophyte plants)
RN 501-36-0 CAPLUS
CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.




L21 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:729704 CAPLUS
DN 135:267273
TI Resveratrol for the treatment of exfoliative eczema, acne or psoriasis
IN Pelliccia, Maria Teresa; Giannella, Attilio; Giannella, Jenny
PA D.B.P. (Development Biotechnological Processes) Di Rossi Valentina E C.
S.N.C., Italy; Nuova Ict S.R.L.
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP 1138323 A2 20011004 EP 2001-106638 20010316 <--
EP 1138323 A3 20011024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
IT 2000MI0630 A1 20010924 IT 2000-MI630 20000324 <--
IT 1318425 B1 20030825
US 2001056071 A1 20011227 US 2001-813948 20010322 <--
PRAI IT 2000-MI630 A 20000324
IT 501-36-0, Resveratrol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(resveratrol for treatment of exfoliative eczema, acne or psoriasis,
and use with other agents)
RN 501-36-0 CAPLUS
CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX
NAME)

10/042,473

Double bond geometry as shown.



L21 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:545461 CAPLUS
DN 135:127168
TI Reduced form of coenzyme Q in highly bioavailable stable dosage forms
IN Chopra, Raj K.
PA USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052822	A1	20010726	WO 2001-US1997	20010118 <--
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	US 6740338	B1	20040525	US 2000-488332	20000120
	CA 2397447	A1	20010726	CA 2001-2397447	20010118 <--
	EP 1251834	A1	20021030	EP 2001-942547	20010118 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
PRAI	US 2000-488332	A	20000120		
	US 2000-637559	A	20000811		
	WO 2001-US1997	W	20010118		
OS	MARPAT 135:127168				
IT	501-36-0, Resveratrol				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(bioavailable stable dosage forms containing ubiquinol)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI)			(CA INDEX NAME)	


Double bond geometry as shown.

L21 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:435062 CAPLUS
DN 135:45986
TI Anti-inflammatory and psoriasis treatment and protein kinase inhibition by
hydroxylstilbenes and novel stilbene derivatives and analogs
IN Chen, Genhui; Webster, John M.; Li, Jianxiong; Hu, Kaiji; Zhu, Jiang
PA Welichem Biotech Inc., Can.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042231	A2	20010614	WO 2000-CA1433	20001206 <--
	WO 2001042231	A3	20011101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2393297	A1	20010614	CA 2000-2393297	20001206 <--
	EP 1248774	A2	20021016	EP 2000-984681	20001206 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003516400	T	20030513	JP 2001-543531	20001206
	AU 780700	B2	20050414	AU 2001-21330	20001206
	US 2003171429	A1	20030911	US 2002-148863	20021028
	US 2005059733	A1	20050317	US 2004-893863	20040715
PRAI	US 1999-168758P	P	19991206		
	US 1999-173300P	P	19991228		
	WO 2000-CA1433	W	20001206		
	US 2002-414632P	P	20021001		
	US 2002-414633P	P	20021001		
	US 2002-148863	B2	20021028		
	WO 2003-CA1497	A2	20030930		
OS	MARPAT 135:45986				
IT	22255-22-7P, 3,4',5-Trimethoxy-trans-stilbene				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxylstilbenes and novel stilbene derivs. and analogs)				

RN 22255-22-7 CAPLUS
 CN Benzene, 1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L21 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:194762 CAPLUS
 DN 134:227409
 TI Oral compositions containing grape polyphenols, collagens, and chitin hydrolyzates
 IN Teraoka, Keiko; Kawai, Yasuhiro
 PA Sunstar, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001072582	A	20010321	JP 1999-252455	19990907 <--
PRAI	JP 1999-252455		19990907		
IT	501-36-0D, Resveratrol, derivs.				
	RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (oral compns. containing grape polyphenols and collagen hydrolyzates and chitin hydrolyzates)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



L21 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:100966 CAPLUS
 DN 134:136742

TI Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses

IN Gantenberg, Nicholas Seymour; Singer, Robert Ernest, Jr.

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008671	A2	20010208	WO 2000-US20658	20000728 <--
	WO 2001008671	A3	20020502		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2379703	A1	20010208	CA 2000-2379703	20000728 <--
	EP 1221949	A2	20020717	EP 2000-948987	20000728 <--
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200200246	T2	20020923	TR 2002-246	20000728 <--
	JP 2003505500	T	20030212	JP 2001-513401	20000728
PRAI	US 1999-364944	A	19990730		
	WO 2000-US20658	W	20000728		

OS MARPAT 134:136742

IT 501-36-0, Resveratrol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition for prophylaxis and treatment of symptoms associated with cold


and

influenza-like illnesses)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L21 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:77951 CAPLUS

DN 134:136704

TI Use of plant polyphenols for treating iron overload

IN Ghisalberti, Carlo

PA Medis S.R.L. Medical Infusion Systems, Italy

SO Eur. Pat. Appl., 13 pp.


CODEN: EPXXDW

10/840,426

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1072265	A1	20010131	EP 1999-830464	19990720 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1074254	A2	20010207	EP 2000-115505	20000719 <--
	EP 1074254	A3	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	EP 1999-830464	A	19990720		
IT	501-36-0, Resveratrol				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(oral compns. containing plant polyphenols for treating iron overload)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:50474 CAPLUS
DN 134:110467
TI Method and compositions using phytosterols and phytoestrogens for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
IN Hughes, Claude L., Jr.; Magoffin, Denis A.
PA Cedars-Sinai Medical Center, USA
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001003687	A2	20010118	WO 2000-US18909	20000712 <--
	WO 2001003687	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

10/14/99 473

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-353004 A 19990713

IT 501-36-0, Resveratrol


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phytosterols and phytoestrogens for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L21 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:869568 CAPLUS

DN 134:46777

TI Stilbene derivatives or plant extracts containing thereof for foods, pharmaceuticals, cosmetics, and oral products

IN Mizutani, Kenichi; Kawai, Yasuhiro

PA Sunstar, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000344622	A	20001212	JP 1999-173734	19990621 <--
PRAI	JP 1999-90415	A	19990331		

OS MARPAT 134:46777

IT 501-36-0, Resveratrol

RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(comps. containing stilbene derivs. or stilbene derivs.-containing plant exts.

and cyclodextrins for foods or pharmaceuticals or cosmetics)

RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L21 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:645846 CAPLUS
 DN 133:242652
 TI Pharmaceutical, dietetic and cosmetic compositions based on tioctic acid and cysteine
 IN Dall'aglio, Roberto; Borgonovo, Margherita; Introini, Carlo; Melegari, Pierangelo
 PA Uni-Ci S.R.L., Italy
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000053176	A1	20000914	WO 2000-EP1637	20000228 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1312377	B1	20020415	IT 1999-MI460	19990305 <--
EP 1156802	A1	20011128	EP 2000-907644	20000228 <--
EP 1156802	B1	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 311874	T	20051215	AT 2000-907644	20000228
ES 2254145	T3	20060616	ES 2000-907644	20000228
EP 1072310	A3	20030108	EP 2000-113660	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI IT 1999-MI460	A	19990305		
WO 2000-EP1637	W	20000228		
IT 501-36-0, Resveratrol				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(pharmaceutical, dietetic and cosmetic compns. based on tioctic acid and cysteine)				
RN 501-36-0 CAPLUS				
CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI)			(CA INDEX NAME)	

Double bond geometry as shown.

10,413,473




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD.
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:592354 CAPLUS
DN 133:198411
TI Use of 3-substituted stilbene derivatives as deodorizing active principles
in cosmetic compositions
IN Courbiere, Christophe; Pruche, Francis; Kravtchenko, Sylvain
PA L'oreal, Fr.
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1029530	A1	20000823	EP 2000-400269	20000201 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2789577	A1	20000818	FR 1999-1931	19990217 <--
	FR 2789577	B1	20020405		
	ZA 2000000603	A	20000905	ZA 2000-603	20000209 <--
	BR 2000001925	A	20010814	BR 2000-1925	20000215 <--
	CN 1270804	A	20001025	CN 2000-106406	20000216 <--
	HU 200000697	A2	20010228	HU 2000-697	20000216 <--
	US 6407142	B1	20020618	US 2000-504724	20000216 <--
	JP 2000247853	A	20000912	JP 2000-40328	20000217 <--
	KR 2000058089	A	20000925	KR 2000-7616	20000217 <--
	US 2002198159	A1	20021226	US 2002-137365	20020503 <--
PRAI	FR 1999-1931	A	19990217		
	US 2000-504724	A3	20000216		
OS	MARPAT 133:198411				
IT	102-61-4, 3,5-Dihydroxystilbene				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)				
	(use of 3-substituted stilbene derivs. as deodorizing active principles in cosmetic compns.)				
RN	102-61-4 CAPLUS				
CN	1,3-Benzenediol, 5-(2-phenylethenyl)- (9CI) (CA INDEX NAME)				

10/942, 47-




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:736469 CAPLUS
DN 131:332106
TI Administration of resveratrol to prevent or treat restenosis following
coronary intervention
IN Goodman, David William
PA Pharmascience Inc., Can.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958119	A1	19991118	WO 1999-CA432	19990512 <--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6022901	A	20000208	US 1998-78300	19980513 <--
	CA 2330487	A1	19991118	CA 1999-2330487	19990512 <--
	AU 9938061	A	19991129	AU 1999-38061	19990512 <--
	EP 1076556	A1	20010221	EP 1999-920493	19990512 <--
	EP 1076556	B1	20040407		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE			
	EP 1338278	A1	20030827	EP 2003-6621	19990512
	R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE			
	AT 263553	T	20040415	AT 1999-920493	19990512
	ES 2215382	T3	20041001	ES 1999-920493	19990512
	US 6211247	B1	20010403	US 1999-434208	19991104 <--
PRAI	US 1998-78300	A	19980513		
	EP 1999-920493	A3	19990512		
	WO 1999-CA432	W	19990512		
IT	501-36-0, trans-Resveratrol				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(resveratrol to prevent or treat restenosis following coronary intervention)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L21 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:722888 CAPLUS
DN 131:332124
TI Arylhydrocarbon receptor ligand antagonists, and therapeutic use
IN Savouret, Jean-Francois; Casper, Robert-Frederic; Milgrom, Edwin
PA Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DT Patent
LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9956737	A1	19991111	WO 1999-FR1063	19990505 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2778337	A1	19991112	FR 1998-5673	19980505 <--
	FR 2778337	B1	20010831		
	CA 2331364	A1	19991111	CA 1999-2331364	19990505 <--
	AU 9935282	A	19991123	AU 1999-35282	19990505 <--
	EP 1075256	A1	20010214	EP 1999-916992	19990505 <--
	EP 1075256	B1	20030730		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002513754	T	20020514	JP 2000-546764	19990505 <--
	AT 245973	T	20030815	AT 1999-916992	19990505
	ES 2205807	T3	20040501	ES 1999-916992	19990505
	AU 2003268599	A1	20040122	AU 2003-268599	20031212
PRAI	FR 1998-5673	A	19980505		
	AU 1999-35282	A3	19990505		
	WO 1999-FR1063	W	19990505		
IT	501-36-0, trans-Resveratrol				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(arylhydrocarbon receptor ligand antagonists, and therapeutic use)				
RN	501-36-0 CAPLUS				
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:48637 CAPLUS
DN 130:100692
TI Pharmaceutical composition containing polyphenols from grapes, in particular resveratrol, and yeast extracts
IN Osterwalder, Nicolo
PA Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A., Italy
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9901148	A1	19990114	WO 1998-EP4065	19980701 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CH 692837	A5	20021129	CH 1997-1598	19970702 <--
EP 925068	A1	19990630	EP 1998-936405	19980701 <--
EP 925068	B1	20030917		
R: IT				
PRAI CH 1997-1598	A	19970702		
WO 1998-EP4065	W	19980701		
IT 501-36-0, Resveratrol				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(pharmaceutical composition containing polyphenols from grapes and yeast exts.)				
RN 501-36-0 CAPLUS				
CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.

10/942,478



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
109.23	357.51

FILE 'STNGUIDE' ENTERED AT 17:26:42 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> log hold
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	357.93

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:31:00 ON 22 DEC 2006